Linda Metheny-Barlow to Middle Aged
This is a "connection" page, showing publications Linda Metheny-Barlow has written about Middle Aged.
Connection Strength
0.061
-
Dohm A, Su J, McTyre ER, Taylor JM, Miller LD, Petty WJ, Xing F, Lo HW, Metheny-Barlow LJ, O'Neill S, Bellinger C, Dotson T, Pasche B, Watabe K, Chan MD, Ruiz J. Identification of CD37, cystatin A, and IL-23A gene expression in association with brain metastasis: analysis of a prospective trial. Int J Biol Markers. 2019 Mar; 34(1):90-97.
Score: 0.016
-
Cramer CK, Alphonse-Sullivan N, Isom S, Metheny-Barlow LJ, Cummings TL, Page BR, Brown DR, Blackstock AW, Peiffer AM, Strowd RE, Rapp S, Lesser GJ, Shaw EG, Chan MD. Safety of pioglitazone during and after radiation therapy in patients with brain tumors: a phase I clinical trial. J Cancer Res Clin Oncol. 2019 Feb; 145(2):337-344.
Score: 0.016
-
Wang EC, Huang AJ, Huang KE, McTyre ER, Lo HW, Watabe K, Metheny-Barlow L, Laxton AW, Tatter SB, Strowd RE, Chan MD, Page BR. Leptomeningeal failure in patients with breast cancer receiving stereotactic radiosurgery for brain metastases. J Clin Neurosci. 2017 Sep; 43:6-10.
Score: 0.014
-
Vern-Gross TZ, Lawrence JA, Case LD, McMullen KP, Bourland JD, Metheny-Barlow LJ, Ellis TL, Tatter SB, Shaw EG, Urbanic JJ, Chan MD. Breast cancer subtype affects patterns of failure of brain metastases after treatment with stereotactic radiosurgery. J Neurooncol. 2012 Dec; 110(3):381-8.
Score: 0.010
-
Marrogi A, Pass HI, Khan M, Metheny-Barlow LJ, Harris CC, Gerwin BI. Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): in vitro antiproliferative effects of a COX-2 inhibitor. Cancer Res. 2000 Jul 15; 60(14):3696-700.
Score: 0.004